ArticleNature communications2014
Monitoring the dynamics of clonal tumour evolution in vivo using secreted luciferases.
Article in Nature communications, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 46 citations in OpenAlex.
- Secreted luciferases as a minimally invasive 3R-compliant tool for accurate monitoring of tumor burden.Nature protocols · 2026Review
- The basal cell state maintains pancreatic cancers by controlling an immunosuppressive circuit.bioRxiv : the preprint server for biology · 2026Article
- Article
- Employing nullclines to balance treatment efficacy and neurotoxicity for sustained tumor control.Mathematical biosciences · 2025Article
- Genetically engineered secretory horseradish peroxidase is a sensitive, stable, and affordable non-lytic reporter gene system for real-time promoter activity management.Journal of biological engineering · 2025Article
- Targeting PI3K inhibitor resistance in breast cancer with metabolic drugs.Signal transduction and targeted therapy · 2025Article
- A Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreatic Cancer.Cancer discovery · 2024Article
- Alveolar Differentiation Drives Resistance to KRAS Inhibition in Lung Adenocarcinoma.Cancer discovery · 2024Article
- Mutant p53-ENTPD5 control of the calnexin/calreticulin cycle: a druggable target for inhibiting integrin-α5-driven metastasis.Journal of experimental & clinical cancer research : CR · 2023Article
- Monitoring autochthonous lung tumors induced by somatic CRISPR gene editing in mice using a secreted luciferase.Molecular cancer · 2022Article
- Using genetically modified extracellular vesicles as a non-invasive strategy to evaluate brain-specific cargo.Biomaterials · 2022Article
- mTOR-mediated cancer drug resistance suppresses autophagy and generates a druggable metabolic vulnerability.Nature communications · 2020Article
- Direct genome editing of patient-derived xenografts using CRISPR-Cas9 enables rapidNature cancer · 2020Article
- Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways.Nature reviews. Clinical oncology · 2019Review
- MYB induces the expression of the oncogenic corepressor SKI in acute myeloid leukemia.Oncotarget · 2018Article
- Biotinylated Bioluminescent Probe for Long Lasting Targeted in Vivo Imaging of Xenografted Brain Tumors in Mice.ACS chemical neuroscience · 2018Article
- Optimized application of the secreted Nano-luciferase reporter system using an affinity purification strategy.PloS one · 2018Article
- Post surgery circulating free tumor DNA is a predictive biomarker for relapse of lung cancer.Cancer medicine · 2017Article
- Mutant p53 promotes tumor progression and metastasis by the endoplasmic reticulum UDPase ENTPD5.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- ΔNp63 activates the Fanconi anemia DNA repair pathway and limits the efficacy of cisplatin treatment in squamous cell carcinoma.Nucleic acids research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumours are heterogeneous cell populations that undergo clonal evolution during tumour progression, metastasis and response to therapy. Short hairpin RNAs (shRNAs) generate stable loss-of-function phenotypes and are versatile experimental tools to explore the contribution of individual genetic alterations to clonal evolution. In these experiments tumour cells carrying shRNAs are commonly tracked with fluorescent reporters. While this works well for cell culture studies and leukaemia mouse models, fluorescent reporters are poorly suited for animals with solid tumours--the most common tumour types in cancer patients. Here we develop a toolkit that uses secreted luciferases to track the fate of two different shRNA-expressing tumour cell clones competitively, both in vitro and in vivo. We demonstrate that secreted luciferase activities can be measured robustly in the blood stream of tumour-bearing mice to accurately quantify, in a minimally invasive manner, the dynamic evolution of two genetically distinct tumour subclones in preclinical mouse models of tumour development, metastasis and therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.